[Effect of DMBA and benz (alpha) anthracene on the biogenic amine level in the rat brain]. 1977

V N Anisimov, and V K Pozdeev, and A Iu Dmitrievskaia, and G M Gracheva, and A P Il'in

Thirty minutes after the administration of DMBA (5 mg i. v.) to rats the level of norepinephrine, dopamine, serotonine (5-HT) and 5-IIIAA in the hypothalamus was decreased, while monoamines levels in the brain stem and hemispheres was unchanged. After benz(a) anthracene (5 mg i.v.) treatment the level of 5-HT in rat hypothalamus was decreased, but catecholamines and 5-HIAA levels were not changed. Pretreatment with L-DOPA abolished the elevation of the threshold of hypothalamic sensitivity to estrogen suppression, induced by 20-methylcholanthrene in rats, and alpha-methyl-DOPA enhanced. It is suggested that the central (hypothalamic) mechanisms participate in the release of the carcinogenic effect of polycylic hydrocarbons in rats.

UI MeSH Term Description Entries
D007031 Hypothalamus Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE. Lamina Terminalis,Preoptico-Hypothalamic Area,Area, Preoptico-Hypothalamic,Areas, Preoptico-Hypothalamic,Preoptico Hypothalamic Area,Preoptico-Hypothalamic Areas
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008748 Methylcholanthrene A carcinogen that is often used in experimental cancer studies. 20-Methylcholanthrene,3-Methylcholanthrene,20 Methylcholanthrene,3 Methylcholanthrene
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002369 Castration Surgical removal or artificial destruction of gonads. Gonadectomy,Castrations,Gonadectomies
D004054 Diethylstilbestrol A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females

Related Publications

V N Anisimov, and V K Pozdeev, and A Iu Dmitrievskaia, and G M Gracheva, and A P Il'in
September 1979, Indian journal of experimental biology,
V N Anisimov, and V K Pozdeev, and A Iu Dmitrievskaia, and G M Gracheva, and A P Il'in
January 1978, European journal of pharmacology,
V N Anisimov, and V K Pozdeev, and A Iu Dmitrievskaia, and G M Gracheva, and A P Il'in
August 1991, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,
V N Anisimov, and V K Pozdeev, and A Iu Dmitrievskaia, and G M Gracheva, and A P Il'in
February 1980, Biulleten' eksperimental'noi biologii i meditsiny,
V N Anisimov, and V K Pozdeev, and A Iu Dmitrievskaia, and G M Gracheva, and A P Il'in
December 1976, Pharmacological research communications,
V N Anisimov, and V K Pozdeev, and A Iu Dmitrievskaia, and G M Gracheva, and A P Il'in
October 2007, African journal of traditional, complementary, and alternative medicines : AJTCAM,
V N Anisimov, and V K Pozdeev, and A Iu Dmitrievskaia, and G M Gracheva, and A P Il'in
December 1983, Biulleten' eksperimental'noi biologii i meditsiny,
V N Anisimov, and V K Pozdeev, and A Iu Dmitrievskaia, and G M Gracheva, and A P Il'in
April 2011, International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience,
V N Anisimov, and V K Pozdeev, and A Iu Dmitrievskaia, and G M Gracheva, and A P Il'in
April 1973, Tsitologiia,
V N Anisimov, and V K Pozdeev, and A Iu Dmitrievskaia, and G M Gracheva, and A P Il'in
November 1976, Psychopharmacology,
Copied contents to your clipboard!